Epigenomcs AG acts as a holding company and is dedicated to managing its own assets, acquiring, holding and disposing of investments in companies in Germany and abroad, particularly in the field of minimally invasive blood tests for cancer detection, as well as investing in other assets.
Latest News
Epigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Gesamtstimmrechte | 10 April 2024 11:33 Epigenomics AG / Total Voting Rights Announcement Epigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 10.04.2024 / 11:33 CET/CEST Total Voting Rights Announcement transmitted by EQS News – a service of EQS Group AG. The issuer […]
Epigenomics AG publishes financial results for fiscal year 2023
EQS-News: Epigenomics AG / Key word(s): Annual Results/Annual ReportEpigenomics AG publishes financial results for fiscal year 2023 14.03.2024 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics AG publishes financial results for fiscal year 2023 Berlin (Germany), March 14, 2024 – Epigenomics AG (FSE: ECX, the “Company”) today reported financial […]
Epigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Gesamtstimmrechte | 12 März 2024 08:51 Epigenomics AG / Total Voting Rights Announcement Epigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 12.03.2024 / 08:51 CET/CEST Total Voting Rights Announcement transmitted by EQS News – a service of EQS Group AG. The issuer […]
Epigenomics AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
Vorabbekanntmachung | 6 März 2024 09:22 Epigenomics AG / Preliminary announcement on the disclosure of financial statements Epigenomics AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] 06.03.2024 / 09:22 CET/CEST Preliminary announcement of the publication of financial reports according to Articles […]
Epigenomics AG: Jochen Hummel appointed to the Supervisory Board to replace Heikki Lanckriet
EQS-News: Epigenomics AG / Key word(s): PersonnelEpigenomics AG: Jochen Hummel appointed to the Supervisory Board to replace Heikki Lanckriet 15.02.2024 / 10:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics AG: Jochen Hummel appointed to the Supervisory Board to replace Heikki Lanckriet Berlin, February 15, 2024 – Epigenomics AG (Frankfurt General […]
Epigenomics AG: Supervisory Board of Epigenomics AG appoints Hansjörg Plaggemars as member of the Executive Board
EQS-News: Epigenomics AG / Key word(s): PersonnelEpigenomics AG: Supervisory Board of Epigenomics AG appoints Hansjörg Plaggemars as member of the Executive Board 31.01.2024 / 15:30 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics AG: Supervisory Board of Epigenomics AG appoints Hansjörg Plaggemars as member of the Executive Board Berlin, January 31, […]
![man-vs-woman](https://www.epigenomics.com/wp-content/themes/epigenomics/images/man-vs-woman.png)